September 14, 2017 / 5:17 PM / 10 days ago

U.S. FDA approves Bayer drug to treat follicular lymphoma

(Reuters) - The U.S. Food and Drug Administration said on Thursday it has approved Bayer AG’s treatment for follicular lymphoma, a cancer of the lymph system.

The drug, Aliqopa, known also as copanlisib, is a kinase inhibitor that blocks certain enzymes that promote cell growth. It is designed for patients who have received at least two prior treatments.

Follicular lymphoma is a slow-growing type of non-Hodgkin lymphoma. An estimated 72,240 people in the United States will be diagnosed with some form of non-Hodgkin lymphoma this year.

The FDA granted Aliqopa accelerated approval, meaning clinical data suggests it will be beneficial, but further trials will be needed to prove that. In a trial of 104 patients, 59 percent experienced a complete or partial shrinkage of their tumors for a median 12.2 months.

Reporting by Toni Clarke in Washington; Editing by Matthew Lewis

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below